Innocan Pharma reported revenue of $4.99M and net income of $1.85M for the quarter ended Dec 2025, down 7.6% year over year. This income statement covers 9 quarters of results from Dec 2023 through Dec 2025, standardized by Business Quant from the company’s SEC filings.
| Income StatementIncome Statement | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue & cost | |||||||||
| Revenue | 6.77M | 8.64M | 8.62M | 5.40M | 7.80M | 7.01M | 6.82M | 4.99M | |
| Cost of RevenueCost of Rev | 0.77M | 0.65M | 0.85M | 0.99M | 0.68M | 0.81M | 0.63M | 0.56M | |
| Gross Profit | 6.00M | 8.00M | 7.78M | 4.41M | 7.12M | 6.20M | 6.19M | 4.43M | |
| Operating items | |||||||||
| Research & DevelopmentR&D | 0.42M | 0.43M | 0.38M | 0.32M | 0.18M | 0.18M | 0.42M | 0.16M | |
| Selling, General & AdministrativeSG&A | 1.48M | 0.94M | 0.88M | 0.82M | 0.74M | 0.70M | 1.48M | 0.66M | |
| Operating ExpensesOpex | 1.90M | 1.37M | 1.26M | 1.15M | 0.92M | 0.87M | 1.90M | 0.82M | |
| Operating IncomeOp. Inc | -1.21M | 0.53M | 0.35M | 1.58M | 0.49M | 0.40M | -1.22M | 1.59M | |
| Non-operating items | |||||||||
| Non Operating Interest Expenses | -0.01M | -0.15M | -0.12M | 0.04M | |||||
| Other Non Operating IncomeOther Non Op Inc. | 0.01M | 0.16M | -0.01M | -0.20M | 0.00M | 0.08M | -0.11M | 0.03M | |
| Non Operating IncomeNon Op. Inc. | -0.05M | 0.16M | 0.01M | 0.09M | |||||
| Net income details | |||||||||
| EBIT | -1.21M | 0.53M | 0.35M | 1.58M | 0.49M | 0.40M | -1.22M | 1.59M | |
| EBT | -1.22M | 1.43M | 0.70M | 0.00M | 0.03M | -0.11M | -1.43M | 1.59M | |
| Tax ProvisionsTaxes | 0.23M | 0.48M | 0.42M | 0.05M | 0.26M | 0.21M | 0.22M | -0.26M | |
| Income After Tax | -1.45M | 0.96M | 0.28M | -0.05M | -0.23M | -0.32M | -1.65M | 1.86M | |
| Income from Continuing OperationsIncome (Continuing) | -1.45M | 0.96M | 0.28M | -0.05M | -0.23M | -0.32M | -1.65M | 1.86M | |
| Consolidated Net IncomeConsol Net Inc. | -1.45M | 0.96M | 0.28M | -0.05M | -0.23M | -0.32M | -1.65M | 1.86M | |
| Net Income Attributable to Noncontrolling InterestsNCI Net Income | 0.31M | 0.62M | 0.57M | 0.07M | 0.35M | 0.28M | 0.30M | -0.14M | |
| Income towards Parent CompanyParent Net Inc | -1.45M | 0.34M | -0.29M | 1.98M | -0.23M | -0.59M | -1.95M | 2.78M | |
| Net Income towards Common StockholdersNet Income | -1.45M | 0.34M | -0.29M | 1.98M | -0.23M | -0.59M | -1.95M | 2.78M | |
| Additional items | |||||||||
| EPS (Basic) | -0.01 | 0.08 | -0.07 | 0.46 | 0.00 | -0.13 | -0.43 | 0.62 | |
| Shares Outstanding | 3.95M | 269.82M | 4.32M | 4.33M | 4.31M | 290.33M | 4.50M | 4.50M | 4.48M |
| EBITDA | -1.20M | 0.54M | 0.36M | 1.58M | 0.50M | 0.41M | -1.21M | 1.60M | |
| Interest ExpensesInt Expense | -0.01M | -0.15M | -0.12M | 0.04M | |||||
| Tax Rate | 33.33% | 59.54% | 1,700.00% | 793.94% |
Pull Innocan Pharma's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/statements?ticker=INNPF&statement=IS&frequency=Quarter&period=all&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/statements"
params = {"ticker": "INNPF", "statement": "IS", "frequency": "Quarter", "period": "all", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/statements?ticker=INNPF&statement=IS&frequency=Quarter&period=all&api_key=YOUR_API_KEY");
const data = await res.json();